Skip to content

Study · Randomized controlled trial · n = 9 · 2017

5 results

Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes.

Thazhath SS, Marathe CS, Wu T, Chang J, Khoo J, Kuo P, Checklin HL, Bound MJ, Rigda RS, Horowitz M, Jones KL, Rayner CK

Diabetes & vascular disease research20 Oct 2016Cited by 12 (Europe PMC)

PMID27941058 (opens in a new tab)DOI10.1177/1479164116666761 (opens in a new tab)PepBankPUB-27941058
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In subjects with type 2 diabetes, exenatide increased diastolic blood pressure versus saline during intraduodenal glucose infusion.

    In plain wordsIn people with type 2 diabetes, exenatide increased diastolic blood pressure versus saline during intestinal glucose infusion.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseDiastolic blood pressure
    Study

    n = 9

    Comparator
    Saline control
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    During intraduodenal glucose infusion (0-60 min), diastolic (p(0-60) = 0.03) and mean arterial (p(0-60) = 0.03) blood pressures and heart rate (p(0-60) = 0.06; p(0-120) = 0.03)) were higher with exenatide compared to placebo.
    2 context sentences
    Summary · context
    Nine subjects with type 2 diabetes were randomised to receive intravenous exenatide or saline control in a crossover design.
    Summary · context
    Glucose (3 kcal min-1) was infused via an intraduodenal manometry catheter for 60 min.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In subjects with type 2 diabetes, exenatide increased mean arterial pressure versus saline during intraduodenal glucose infusion.

    In plain wordsIn people with type 2 diabetes, exenatide increased mean arterial pressure versus saline during intestinal glucose infusion.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseMean arterial blood pressure
    Study

    n = 9

    Comparator
    Saline control
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    During intraduodenal glucose infusion (0-60 min), diastolic (p(0-60) = 0.03) and mean arterial (p(0-60) = 0.03) blood pressures and heart rate (p(0-60) = 0.06; p(0-120) = 0.03)) were higher with exenatide compared to placebo.
    2 context sentences
    Summary · context
    Nine subjects with type 2 diabetes were randomised to receive intravenous exenatide or saline control in a crossover design.
    Summary · context
    Glucose (3 kcal min-1) was infused via an intraduodenal manometry catheter for 60 min.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In subjects with type 2 diabetes, heart rate was higher with exenatide, with significance over 0-120 minutes but not 0-60 minutes.

    In plain wordsIn people with type 2 diabetes, exenatide raised heart rate versus saline, with significance over the longer observation period.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHeart rate
    Study

    n = 9

    Comparator
    Saline control
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    During intraduodenal glucose infusion (0-60 min), diastolic (p(0-60) = 0.03) and mean arterial (p(0-60) = 0.03) blood pressures and heart rate (p(0-60) = 0.06; p(0-120) = 0.03)) were higher with exenatide compared to placebo.
    2 context sentences
    Summary · context
    Nine subjects with type 2 diabetes were randomised to receive intravenous exenatide or saline control in a crossover design.
    Summary · context
    Glucose (3 kcal min-1) was infused via an intraduodenal manometry catheter for 60 min.
  4. 04HumanRandomized controlled trialMechanism

    In subjects with type 2 diabetes, increased diastolic pressure area under the curve related directly to exenatide-induced duodenal motility suppression versus control.

    In plain wordsIn people with type 2 diabetes, exenatide-related diastolic pressure increases related to reduced intestinal movement versus control.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableDiastolic pressure and duodenal motility association
    Study

    n = 9

    Comparator
    Saline control
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    The increase in the area under the curve for diastolic blood pressure and mean arterial blood pressure was related directly to the suppression of the duodenal motility index with exenatide compared to control (p = 0.007 and 0.04, respectively).
    2 context sentences
    Summary · context
    Nine subjects with type 2 diabetes were randomised to receive intravenous exenatide or saline control in a crossover design.
    Summary · context
    Glucose (3 kcal min-1) was infused via an intraduodenal manometry catheter for 60 min.
  5. 05HumanRandomized controlled trialMechanism

    In subjects with type 2 diabetes, increased mean arterial pressure area under the curve related directly to exenatide-induced duodenal motility suppression versus control.

    In plain wordsIn people with type 2 diabetes, exenatide-related mean arterial pressure increases related to reduced intestinal movement versus control.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableMean arterial pressure and duodenal motility association
    Study

    n = 9

    Comparator
    Saline control
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    The increase in the area under the curve for diastolic blood pressure and mean arterial blood pressure was related directly to the suppression of the duodenal motility index with exenatide compared to control (p = 0.007 and 0.04, respectively).
    2 context sentences
    Summary · context
    Nine subjects with type 2 diabetes were randomised to receive intravenous exenatide or saline control in a crossover design.
    Summary · context
    Glucose (3 kcal min-1) was infused via an intraduodenal manometry catheter for 60 min.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.